PCVX VAX-31 targets dominant pneumococcal market share
PCVX said its VAX-31 aims for dominant market share with broader pneumococcal vaccine coverage. The company expects pivotal phase III data for VAX-31 by October.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.